| Leila Sheridan Hardware, DO | |
|
713 Bethlehem Pike, Montgomeryville, PA 18936-9602 | |
| (267) 695-3944 | |
| Not Available |
| Full Name | Leila Sheridan Hardware |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 713 Bethlehem Pike, Montgomeryville, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780844571 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS-014588 (Pennsylvania) | Primary |
| Entity Name | City Of Philadelphia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942317094 PECOS PAC ID: 6305758723 Enrollment ID: O20040220000911 |
News Archive
Tumor cells divide fast. They thus require a high supply of components for their DNA, like purines. The biosynthesis of purines could now be a new point of attack for chemotherapy. However, without a natural model, the search for an inhibitor for a cellular process is like the proverbial search for a needle in a haystack. An American research team has developed a clever way to quickly conjure the desired "needle" out of the hay, presenting several candidates to act as starting points for the design of a purine synthesis inhibitor.
In this post on the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Kent Campbell, director of the Malaria Control Program at PATH, says "dramatic gains" made in the fight against malaria, and the possibility of ending the disease, are in jeopardy because the "Global Fund to Fight AIDS, Tuberculosis and Malaria, which provides two-thirds of the global financing for efforts to combat malaria, is facing a financial crisis due to unfulfilled donor commitments."
Eurand has announced that Eurand Pharmaceuticals Ltd. initiated the rolling submission of its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for Zentase for the treatment of Exocrine Pancreatic Insufficiency (EPI). Zentase (formerly EUR-1008), the company's lead product candidate, has been granted fast-track designation by the FDA.
Additional important milestones have been reached on the road to success, and the pace continues to be fast. By setting up a sales branch office in France, Optics Balzers as a provider of innovative optical thin-film components and assemblies continues to forge ahead with expanding its presence in Europe.
Patients can assess their own back pain using an app on their phone or tablet as effectively as current paper methods, a new study from the University of Warwick has shown.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leila Sheridan Hardware, DO 131 E Chelten Ave, Philadelphia, PA 19144-2153 Ph: (215) 685-5700 | Leila Sheridan Hardware, DO 713 Bethlehem Pike, Montgomeryville, PA 18936-9602 Ph: (267) 695-3944 |
News Archive
Tumor cells divide fast. They thus require a high supply of components for their DNA, like purines. The biosynthesis of purines could now be a new point of attack for chemotherapy. However, without a natural model, the search for an inhibitor for a cellular process is like the proverbial search for a needle in a haystack. An American research team has developed a clever way to quickly conjure the desired "needle" out of the hay, presenting several candidates to act as starting points for the design of a purine synthesis inhibitor.
In this post on the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Kent Campbell, director of the Malaria Control Program at PATH, says "dramatic gains" made in the fight against malaria, and the possibility of ending the disease, are in jeopardy because the "Global Fund to Fight AIDS, Tuberculosis and Malaria, which provides two-thirds of the global financing for efforts to combat malaria, is facing a financial crisis due to unfulfilled donor commitments."
Eurand has announced that Eurand Pharmaceuticals Ltd. initiated the rolling submission of its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for Zentase for the treatment of Exocrine Pancreatic Insufficiency (EPI). Zentase (formerly EUR-1008), the company's lead product candidate, has been granted fast-track designation by the FDA.
Additional important milestones have been reached on the road to success, and the pace continues to be fast. By setting up a sales branch office in France, Optics Balzers as a provider of innovative optical thin-film components and assemblies continues to forge ahead with expanding its presence in Europe.
Patients can assess their own back pain using an app on their phone or tablet as effectively as current paper methods, a new study from the University of Warwick has shown.
› Verified 7 days ago
Dana Lynn Mincer, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 713 Bethlehem Pike, Montgomeryville, PA 18936 Phone: 267-695-3944 | |
Isaiah J. Abney, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 713 Bethlehem Pike, Montgomeryville, PA 18936 Phone: 267-695-3944 | |
Lawton O. Delisser, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 713 Bethlehem Pike, Suite 200, Montgomeryville, PA 18936 Phone: 267-695-3944 Fax: 267-695-3945 | |
Florita Cordero Lopez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 713 Bethlehem Pike, Montgomeryville, PA 18936 Phone: 267-695-3944 Fax: 267-695-3945 | |
Cary A Davidson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 713 Bethlehem Pike, Montgomeryville, PA 18936 Phone: 267-695-3944 Fax: 267-695-3945 |